Vatalanib

Generic Name: Vatalanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₅ClN_₄

CAS Number: 212141-54-3

Unique Ingredient Identifier: 5DX9U76296

Background: Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

Indication: Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Stage IV Renal Cell Cancer
Thyroid Gland Medullary Carcinoma
Unspecified Adult Solid Tumor, Protocol Specific
Gastrinoma
Insulinoma
Metastatic Gastrointestinal Carcinoid Tumor
Metastatic Pheochromocytoma
Recurrent Gastrointestinal Carcinoid Tumor
Stage III Neuroendocrine Carcinoma of the Skin
Stage IV Melanoma

Interventions: Drug: everolimus
Drug: vatalanib
Other: pharmacological study
Other: laboratory biomarker analysis
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Procedure: ultrasound imaging

First Posted Date: 2008-04-10

Last Posted Date: 2024-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 96

Registration Number: NCT00655655

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Metastatic Neuroendocrine Tumors

Interventions: Drug: vatalanib

First Posted Date: 2008-01-10

Last Posted Date: 2011-06-29

Lead Sponsor: Louisiana State University Health Sciences Center in New Orleans

Target Recruit Count: 23

Registration Number: NCT00590343

Locations: 🇺🇸
Neuroendocrine Clinic, Kenner, Louisiana, United States

Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2007-11-26

Last Posted Date: 2013-08-02

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 34

Registration Number: NCT00563823

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-01-24

Last Posted Date: 2009-11-19

Lead Sponsor: Novartis

Target Recruit Count: 24

Registration Number: NCT00426452

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: vatalanib
Drug: pemetrexed disodium
Other: pharmacological study
Procedure: ultrasound imaging

First Posted Date: 2006-10-19

Last Posted Date: 2019-04-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 29

Registration Number: NCT00390000

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: hydroxyurea
Drug: imatinib mesylate
Drug: vatalanib

First Posted Date: 2006-10-13

Last Posted Date: 2015-10-14

Lead Sponsor: Duke University

Target Recruit Count: 37

Registration Number: NCT00387933

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Sarcoma

Interventions: Drug: vatalanib

First Posted Date: 2006-07-06

Last Posted Date: 2018-10-26

Lead Sponsor: Northwestern University

Target Recruit Count: 25

Registration Number: NCT00348790

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2012-10-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT00293371

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2

Withdrawn

Conditions: Gastrointestinal Carcinoid Tumor
Islet Cell Carcinoma

First Posted Date: 2005-09-28

Last Posted Date: 2015-10-08

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00227773

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Vatalanib
Drug: Gemcitabine

First Posted Date: 2005-09-16

Last Posted Date: 2014-09-15

Lead Sponsor: George Albert Fisher

Target Recruit Count: 33

Registration Number: NCT00185588

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy